↗8 Form 4 rows in the window
Covers original filings from Aug 1, 2026 to Oct 29, 2026. Older trades and amendments are in the SEC history.
$0.00Bought on the market
$1.8MSold on the market
1Companies
Oct 2, 2026Latest filing
| Company | Title | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 202616:09 | Oct 1, 2026 | MAZEMaze Therapeutics, Inc. | President, R&D & CMO | S · Sell10b5-1 | $26.93 | −16,141 | 0 | -100% | −$435K | ||
| Oct 2, 202616:09 | Oct 1, 2026 | MAZEMaze Therapeutics, Inc. | President, R&D & CMO | M · Exercise10b5-1 | $10.42 | +16,141 | 16,141 | New | $168K | ||
| Sep 8, 202616:20 | Sep 4, 2026 | MAZEMaze Therapeutics, Inc. | President, R&D & CMO | S · Sell10b5-1 | $26.22 | −9,705 | 0 | -100% | −$255K | ||
| Sep 4, 202616:22 | Sep 3, 2026from Sep 2, 2026 | MAZEMaze Therapeutics, Inc. | President, R&D & CMO | S · Sell | $26.24 | −10,295 | 9,705 | -51% | −$270K | ||
| Sep 3, 202616:24 | Sep 1, 2026 | MAZEMaze Therapeutics, Inc. | President, R&D & CMO | S · Sell10b5-1 | $26.36 | −16,141 | 0 | -100% | −$426K | ||
| Sep 3, 202616:24 | Sep 1, 2026 | MAZEMaze Therapeutics, Inc. | President, R&D & CMO | M · Exercise10b5-1 | $4.65 | +36,141 | 20,000 | — | $168K | ||
| Aug 14, 202616:54 | Aug 13, 2026 | MAZEMaze Therapeutics, Inc. | President, R&D & CMO | S · Sell10b5-1 | $27.61 | −16,142 | 0 | -100% | −$446K | ||
| Aug 14, 202616:54 | Aug 13, 2026 | MAZEMaze Therapeutics, Inc. | President, R&D & CMO | M · Exercise10b5-1 | $10.42 | +16,142 | 16,142 | New | $168K |